



Interleukin 17-A (IL-17A) in Psoriasis

A messenger protein (or cytokine) found to play a key role in psoriasis and other autoimmune diseases¹

How increased levels of IL-17A affect the skin in psoriasis²⁻⁴



IL-17A can affect other parts of the body^{3,4}



Higher IL-17A levels may cause more severe psoriasis symptoms^{5,6}



IL-17A: A new potential target

Newer, innovative treatments have been developed in response to this unmet need. These treatments specifically target the cytokines that trigger inflammation, such as IL-17A, and interrupt the inflammatory cycle in psoriasis. They have shown positive results in the treatment and management of psoriasis⁴.

1. Kirkham BW, Kavanaugh A, Reich K. Immunology. 2014; 141:133-142.
 2. Onishi RM, Gaffen SL. Immunology. 2010; 129: 311-21.
 3. Nestle FO, Kaplan DH, Barker J. N Engl J Med 2009; 361(5):496-509.
 4. Arthritis Foundation. FDA Approves Biologic Secukinumab for Ankylosing Spondylitis and Psoriatic Arthritis. Available at: <http://blog.arthritis.org/news/new-biologic-medication-fdaapproved-secukinumab/>. Accessed February 2016.
 5. National Psoriasis Foundation. The immune system and psoriatic disease. Accessed February 2016
 6. Kopf M, Bachmann MF, Marsland BJ. Nat Rev Drug Discov. 2010; 9(9):703-18.